Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
This study will explore how genes may influence the severity of ankylosing spondylitis, a form of arthritis that affects the spine. Patients have inflammation of the joints of the spine, which may cause the bones of the spine to fuse, resulting in difficulty performing daily activities.
Patients who developed ankylosing spondylitis after age 16 may be eligible for this study. The onset of disease is dated to the first appearance of symptoms of inflammatory low back pain or restricted spinal motion. Patients with a spondyloarthropathy other than AS may not participate. Candidates will be screened with a medical history and physical examination, blood test, and review of their medical records. They will also complete a questionnaire about their disease symptoms and medical history.
Those enrolled in the study will return to the NIH Clinical Center at 6, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months after screening for examination of the joints, measurement of flexibility of the spine, and a blood test. They will also complete symptoms assessment and coping questionnaires. At the first study visit (screening visit), x-rays will be taken of the pelvis, lower back, and neck, if recent X-rays (within 1 year) are not available. These x-ray studies will be repeated on all patients every two years during the study (at 24 and 48 months after screening).
|Study Design:||Time Perspective: Prospective|
|Official Title:||Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study|
|Study Start Date:||March 2003|
The susceptibility to ankylosing spondylitis (AS) is largely genetically determined. Recent studies suggest that the severity of AS is also influenced by genetic factors. The goal of this study is to identify genes that influence the severity of AS. We hypothesize that genetic markers of susceptibility, including human leukocyte antigen (HLA) polymorphisms, and genes that regulate inflammation and bone formation, influence the severity of AS.
In this prospective longitudinal study, we will test the association of several genetic markers with the severity of AS. Approximately 700 patients will be included. Measures of AS severity will be patient-reported pain and stiffness, functional disability, patient and physician global assessments, joint counts, number of tender entheses, spinal mobility, and laboratory measures of inflammation. These measures will be assessed every 6 months for 5 years. We will also evaluate new laboratory tests as measures of the activity of AS.
Identifying genetic markers that are associated with differences in the severity of active inflammation in AS will enhance our understanding of the pathogenesis of this disease by suggesting mechanisms and pathways involved in the development of long-term damage.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00056719
|Contact: Nancy A Spencer||(301) firstname.lastname@example.org|
|Contact: Michael M Ward, M.D.||(301) email@example.com|
|United States, California|
|Cedars Sinai Medical Center||Recruiting|
|Los Angeles, California, United States, 90048-1804|
|Contact: Kristina Van Citters 301-423-2422 firstname.lastname@example.org|
|University of California, San Francisco||Recruiting|
|San Francisco, California, United States, 94143|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 email@example.com|
|United States, Texas|
|University of Texas Health Science Center - Houston||Recruiting|
|Houston, Texas, United States|
|Contact: Laura Diekman 713-500-6852 firstname.lastname@example.org|
|Queensland University of Technology||Recruiting|
|Principal Investigator:||Michael M Ward, M.D.||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|